Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Johnson & johnson    crawled time : 16:20    save search
FDA Greenlights BMS, J&J CAR-T Therapies for Earlier Multiple Myeloma Treatment
Published: 2024-04-06 (Crawled : 16:20) - biospace.com/
JNJ | News | $149.575 0.31% 2.5M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
fda treatment for car-t
Antibody Therapeutics Market Size to Grow USD 364180 Million by 2029 at a CAGR of 11% | Valuates Reports
Published: 2024-01-21 (Crawled : 16:20) - prnewswire.com
JNJ | News | $149.575 0.31% 2.5M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
AZNCF | News | $138.73 3.7K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
AZN | News | $70.54 0.59% 1.7M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
antibody million therapeutics market
KENVUE SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Kenvue To Contact Him Directly To Discuss Their Options
Published: 2023-11-18 (Crawled : 16:20) - prnewswire.com
XPEL | $53.95 0.71% 22K twitter stocktwits trandingview |
Consumer Durables
 | Email alert Add to watchlist
INSE M | $9.025 1.29% 85K twitter stocktwits trandingview |
Technology Services
 | Email alert Add to watchlist
JNJ | News | $149.575 0.31% 2.5M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
KVUE 4 | $19.555 -0.13% 3.5M twitter stocktwits trandingview |
n/a
 | Email alert Add to watchlist
Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Kenvue Inc.
Published: 2023-10-29 (Crawled : 16:20) - prnewswire.com
DFS | $127.95 1.0% 130K twitter stocktwits trandingview |
Finance
 | Email alert Add to watchlist
JNJ | News | $149.575 0.31% 2.5M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
HE | $10.855 0.23% 350K twitter stocktwits trandingview |
Utilities
 | Email alert Add to watchlist
KVUE 4 | $19.555 -0.13% 3.5M twitter stocktwits trandingview |
n/a
 | Email alert Add to watchlist
New Data from Phase 3 PAPILLON Study Show RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in 60 Percent Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer
Published: 2023-10-21 (Crawled : 16:20) - prnewswire.com
JNJ | News | $149.575 0.31% 2.5M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
rybrevant lung disease cancer cell risk plus show study
New Long-Term Data from the CHRYSALIS Study Show Median Progression-Free Survival Not Reached after 33.6 Months of Follow-Up with First-Line Use of RYBREVANT® (amivantamab-vmjw) and Lazertinib Combination Therapy in Patients with Treatment-Naïve EGFR-Mutated Advanced Non-Small Cell Lung Cancer
Published: 2023-06-04 (Crawled : 16:20) - prnewswire.com
JNJ | News | $149.575 0.31% 2.5M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
rybrevant lung cancer cell therapy show study
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important March 22 Deadline in Securities Class Action - FATE
Published: 2023-03-18 (Crawled : 16:20) - prnewswire.com
CRL | News | $239.81 3.12% 170K twitter stocktwits trandingview |
Commercial Services
 | Email alert Add to watchlist
JNJ | News | $149.575 0.31% 2.5M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
FATE | News | $4.825 0.94% 480K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
deadline
ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important March 22 Deadline in Securities Class Action - FATE
Published: 2023-03-11 (Crawled : 16:20) - prnewswire.com
JNJ | News | $149.575 0.31% 2.5M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
FATE | News | $4.825 0.94% 480K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
trusted deadline
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
Published: 2023-03-05 (Crawled : 16:20) - prnewswire.com
JNJ | News | $149.575 0.31% 2.5M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
xarelto plus
Pulnovo Medical Announces Dr. Mingdong Zhang, Former FDA Medical Device Officer Joins Scientific Advisory Board
Published: 2023-01-14 (Crawled : 16:20) - prnewswire.com
BSX | $68.58 0.82% 2M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
JNJ | News | $149.575 0.31% 2.5M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
fda device medical
Female contraceptive market size to grow by USD 5,142.22 million: Personal products industry is the parent market - Technavio
Published: 2022-12-10 (Crawled : 16:20) - prnewswire.com
ABBV | News | $169.965 1.24% 890K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
AMGN | News | $273.19 0.47% 360K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
VERU | $1.415 11.42% 1.4M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
TEVJF | News | $12.37 -24.22% 380 twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
JNJ | News | $149.575 0.31% 2.5M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
RBGLY | News | $10.59 850K twitter stocktwits trandingview |
Manufacturing
 | Email alert Add to watchlist
RBGPF | News | $52.06 4.8K twitter stocktwits trandingview |
Consumer Non-Durables
 | Email alert Add to watchlist
contraceptive market
New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia
Published: 2022-12-10 (Crawled : 16:20) - prnewswire.com
JNJ | News | $149.575 0.31% 2.5M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
FNCTF | News | $11.16 130 twitter stocktwits trandingview |
Communications
 | Email alert Add to watchlist
imbruvica treatment glow leukemia response plus results study
Janssen Announces Late-Breaking Data from Two Gene Therapy Programs at the American Academy of Ophthalmology 2022 Annual Meeting
Published: 2022-10-01 (Crawled : 16:20) - prnewswire.com
JNJ | News | $149.575 0.31% 2.5M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
MGTX | $4.96 -1.2% 30K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
meeting therapy
Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)
Published: 2022-10-01 (Crawled : 16:20) - globenewswire.com
JNJ | News | $149.575 0.31% 2.5M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
MGTX | $4.96 -1.2% 30K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
therapy
MIT Solve Selects New Class of 40 Tech-Based Social Entrepreneurs Addressing Global Challenges with over $2 Million in Funding
Published: 2022-09-18 (Crawled : 16:20) - prnewswire.com
JNJ | News | $149.575 0.31% 2.5M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
global funding
At 8.6% CAGR, Global Tissue Sealants and Tissue Adhesive Market Size & Share to Surpass USD 2.9 Billion by 2028 | Industry Trends, Growth, Value, Opportunities, Statistics, Analysis & Forecast Report by ZMR
Published: 2022-06-11 (Crawled : 16:20) - prnewswire.com
BAX | $40.755 0.88% 450K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
LUNA | $2.305 -5.73% 130K twitter stocktwits trandingview |
Electronic Technology
 | Email alert Add to watchlist
JNJ | News | $149.575 0.31% 2.5M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
report market
Updated Data for Janssen's Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Published: 2022-06-05 (Crawled : 16:20) - prnewswire.com
JNJ | News | $149.575 0.31% 2.5M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
GMAB | News | $28.82 -0.52% 120K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
GNMSF | News | $289.67 5.3K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
treatment
Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI™ (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
Published: 2022-06-04 (Crawled : 16:20) - prnewswire.com
JNJ | News | $149.575 0.31% 2.5M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
Results of Novel Clinical Study Show Adults with Moderately to Severely Active Ulcerative Colitis Achieved Higher Rates of Clinical Response, Clinical Remission, and Endoscopic Improvement at 12 Weeks with Guselkumab and Golimumab Combination Therapy Versus Either Monotherapy Alone
Published: 2022-02-19 (Crawled : 16:20) - prnewswire.com
JNJ | News | $149.575 0.31% 2.5M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
response active one therapy pons results ulcerative colitis
New Data from Phase 3 GLOW Study Show Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrated Deeper and Sustained Undetectable Minimal Residual Disease Outcomes in First-Line Chronic Lymphocytic Leukemia
Published: 2021-12-11 (Crawled : 16:20) - prnewswire.com
JNJ | News | $149.575 0.31% 2.5M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
imbruvica treatment leukemia disease phase 3
Gainers vs Losers
87% 13%

Top 10 Gainers
MTTR | News M | $4.595 164.08% 13M twitter stocktwits trandingview |

AGBA | $2.355 88.4% 34M twitter stocktwits trandingview |
Finance
EDBL | News | $6.75 79.52% 1.5M twitter stocktwits trandingview |

CZOO | $8.77 75.75% 11M twitter stocktwits trandingview |

MTC | $2.28 46.15% 2.6M twitter stocktwits trandingview |
Technology Services
OPRT | News | $3.14 39.56% 7.6M twitter stocktwits trandingview |
Finance
VNRX | $0.8 33.33% 2.9M twitter stocktwits trandingview |
Health Technology
MLEC | $1.865 33.21% 2.4M twitter stocktwits trandingview |
n/a
PALI | $6.37 29.21% 21M twitter stocktwits trandingview |
Manufacturing
CMAX | $4.12 28.35% 65K twitter stocktwits trandingview |
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.